A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Study sponsor: Arvinas Inc. · ARVN
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2026-10-30Actual
Enrollment · participants76Actual
Source updated2026-11-17Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.